Evidence map›Paper›PMID 30794709›Full record

ArticlePloS one2019

Recurrence of depression in the perinatal period: Clinical features and associated vulnerability markers in an observational cohort.

Nina M Molenaar, Marlies E Brouwer, Astrid M Kamperman, Huibert Burger, Alishia D Williams, Witte J G Hoogendijk, Claudi L H Bockting, Mijke P Lambregtse-van den Berg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Nina M MolenaarThe Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2531-9467
Marlies E BrouwerThe Department of Psychiatry, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Astrid M KampermanThe Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
Huibert BurgerThe Department of Psychiatry, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-6484-0349
Alishia D WilliamsFaculty of Science, School of Psychology, The University of New South Wales, Sydney, Australia.
Witte J G HoogendijkThe Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
Claudi L H BocktingThe Department of Psychiatry, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Mijke P Lambregtse-van den BergThe Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLAmsterdam University Medical Centers · NLUniversity Medical Center Groningen · NLUNSW Sydney · AUUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAntidepressant medication is commonly used for the prevention of depression recurrence in the perinatal period, yet it is unknown what vulnerability markers may play a role in recurrence. The objective of the current study was to provide a descriptive overview of the associated characteristics of women who experienced a perinatal recurrence of depression despite ongoing antidepressant use, and further, to identify clinically measurable vulnerability markers associated with recurrence.

methodsEighty-five pregnant women with a history of depression who used antidepressants (e.g. Selective Serotonin Reuptake Inhibitors or Serotonin and Noradrenaline Reuptake Inhibitors) at the start of the study were included. Clinical features, including information on psychiatric history and antidepressant use, were collected throughout the perinatal period (in this study defined as the period between 12 weeks of pregnancy untill three months postpartum). The clinical features of women experiencing recurrence of depression were described in detail. To identify vulnerability markers associated with recurrence of depression, we performed exploratory univariable logistic regression analyses.

resultsEight women (9.4%) experienced a recurrence of depression; two during pregnancy and six in the first 12 weeks postpartum. All women with recurrence of depression had first onset of depression during childhood or adolescence and had at least 2 psychiatric co-morbidities. Identification of vulnerability markers associated with recurrence of depression yielded associations with depressive symptoms around 16 weeks of pregnancy (OR 1.28, 95%CI 1.08-1.52), number of psychiatric co-morbidities (OR 1.89, 95%CI 1.16-3.09) and duration of antidepressant use (OR 1.01, 95%CI 1.00-1.02).

conclusionImplementing adequate risk assessment in pregnant women who use antidepressants can help identify predictors for recurrence of depression in future studies and thus ultimately lead to improved care.

Indexed as

AdultAntidepressive AgentsDepressionDepression, PostpartumFemaleHumansParityParturitionPregnancyPregnancy ComplicationsRecurrenceRisk AssessmentSelective Serotonin Reuptake InhibitorsSerotoninAntidepressive AgentsSelective Serotonin Reuptake InhibitorsSerotonin

Identifiers

PMID30794709
PMCPMC6386367
OpenAlexW2918119983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.